SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

I'm interested

12 Years to 100 Years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Have a diagnosis of hemophilia A or B with inhibitors.
• Be 12 years of age and older
• Be capable of understanding and willing to comply with the conditions of the protocol or have a legal guardian who is capable of understanding and complying with the conditions of the protocol
• Have read, understood, and documented written informed consent/assent
• Be able to provide medical evidence through prior medical history of previous inhibitor levels
• Be willing and able to use the ATHN mobile application or a paper diary to document BEs and medication usage
Exclusion Criteria:

• Have a disorder of hemostasis in addition to Hemophilia A or B
• Have a known or suspected intolerance or hypersensitivity to SEVENFACT® or its ingredients
• Have a known allergy or hypersensitivity to rabbits or rabbit proteins
• Are receiving prophylactic treatment for bleeding with a drug or biologic that is not approved for this use by the FDA
• Have had implantation of an investigational medical device within the prior 6 months
• Have received an investigational drug within 30 days of the baseline visit
• Have an elective surgical procedure planned during the duration of their participation in the study*
• Have any life-threatening disease, or other disease or condition which, in the investigator's judgment, could pose a potential hazard to the patient or interfere with study participation or study outcome (e.g., a history of non responsiveness to bypassing products or thromboembolic disease)
• Should a participant require an unplanned surgery, the participant will not be withdrawn from the study unless the investigator deems it necessary. Instead, the participant will receive standard of care treatment as determined by the attending physician. If the participant is not withdrawn from the study, the participant's participation in the study will be paused until the investigator feels it is safe for them to continue.

Drug: coagulation factor VIIa [recombinant]-jncw

Hemophilia A With Inhibitor, Hemophilia B With Inhibitor

Hemophilia A, Hemophilia B, bleeding event, prophylactic treatment

Carol Fedor, ND, RN, CCRC -
Jessica Callis -
Phase 4
See this study on